Days ago Reuters The U.S. Food and Drug Administration on Wednesday approved Johnson Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy. The approval comes when Johnson Johnson's blockbuster prostate . On , the U.S. Food and Drug Administration approved neratinib NERLYNX, Puma Biotechnology, Inc. for the extended adjuvant treatment of adult patients with early stage HER overexpressed amplified breast cancer, to follow adjuvant trastuzumab based therapy. Approval was based on . The U.S. Food and Drug Administration today approved Besponsa inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia ALL . The safety and efficacy of Besponsa were stu.d in a randomized trial of patients . The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life threatening diseases..
Related posts to FDA approves J&J prostate cancer treatment
FDA Drug Safety Communication FDA approves label changes to include intestinal problems sprue like enteropathy linked to blood .
Note Press announcements from are available through the FDA.gov Archive. Some links in press announcements may no longer be active..
FDA Approves Botox to Treat Chronic Migraines. Injections of Botox Can Relieve Migraine Headache Symptoms for up to Months.
FDA Approves Praxbind idarucizumab , Specific Reversal Agent for Pradaxa dabigatran etexilate First FDA approval of a specific reversal agent for a novel .